ERBB2 and breast carcinoma: To investigate heterogeneity and drug sensitivity, Mimoto and colleagues generated CRCs from patients with recurrent HR+/HER2- (hormone receptor-positive/human epidermal receptor 2-negative) breast cancer [106].